Patient and Transplant Characteristics
| Parameter . | GVDH Prophylaxis . | |
|---|---|---|
| . | CSP . | CSP Plus MP . |
| No. of patients | 60 | 62 |
| Gender (M/F) (no. of patients) | 39/21 | 39/23 |
| Age (yrs) | ||
| Range (median) | 0.9-57 (36) | 12-59 (39) |
| Diagnoses (no. of patients)* | ||
| ALL | 15 (9)† | 13 (7) |
| ANL | 9 (4) | 9 (4) |
| CML | 2 | 2 |
| Hodgkin/NHL | 21 (3) | 20 (4) |
| MDS‡ | 11 | 15 |
| Other | 2 | 3 |
| Conditioning regimen (no. of patients) | ||
| CY/TBIρ | 37 | 28 |
| BU/CY/TBI1-155 | 14 | 20 |
| BU/CY | 5 | 5 |
| CY/TBI1-154 | 0 | 2 |
| Other chemotherapy1-167 | 4 | 7 |
| LAF | 5 | 7 |
| IVIg1-160 | 5 | 5 |
| Parameter . | GVDH Prophylaxis . | |
|---|---|---|
| . | CSP . | CSP Plus MP . |
| No. of patients | 60 | 62 |
| Gender (M/F) (no. of patients) | 39/21 | 39/23 |
| Age (yrs) | ||
| Range (median) | 0.9-57 (36) | 12-59 (39) |
| Diagnoses (no. of patients)* | ||
| ALL | 15 (9)† | 13 (7) |
| ANL | 9 (4) | 9 (4) |
| CML | 2 | 2 |
| Hodgkin/NHL | 21 (3) | 20 (4) |
| MDS‡ | 11 | 15 |
| Other | 2 | 3 |
| Conditioning regimen (no. of patients) | ||
| CY/TBIρ | 37 | 28 |
| BU/CY/TBI1-155 | 14 | 20 |
| BU/CY | 5 | 5 |
| CY/TBI1-154 | 0 | 2 |
| Other chemotherapy1-167 | 4 | 7 |
| LAF | 5 | 7 |
| IVIg1-160 | 5 | 5 |
Abbreviations: LAF, laminar air flow room; ALL, acute lymphoblastic leukemia; ANC, acute nonlymphoblastic leukemia; CML, chronic myelogenous leukemia; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; CY, cyclophosphamide; BU, busulfan.
Patients were stratified by disease status.
Numbers of patients in remission are in parenthesis.
Refractory anemia with excess blasts (RAEB) or RAEB in transformation.
ρ 1,200 to 1,575 cGy.
1,200 to 1,500 cGy.
1,350 to 1,575 cGy.
ATG/BU/CY; ATG/CY; BCNU/CY/VP16.
500 mg/kg IV weekly.